论文部分内容阅读
许多临床研究表明,铜在某些方面与肿瘤的临床过程相关。在淋巴瘤和一些实体瘤、特别是乳腺癌、胃肠道癌和肺癌,病人血清铜(Scu)含量都升高。Scu 似乎与肿瘤的临床病程和范围相关,因而被认为是肿瘤病人预后的较好指标之一。本文旨在探讨Scu对长期肝功能紊乱病人的预测价值、对肝癌与肝硬变鉴别诊断的应用以及与肝癌病人的存活时间是否相关.作者共报道36例原发性肝癌患者,其中男性25例,女性11例,年龄14～75岁,32例为肝细胞癌,其中10例同时有肝硬变,4例为胆管癌。15例病人进行了外科手术治疗。47例肝硬变病人为对照组,其中男性31例,女性16例,都经CT、超声X 线断层摄影、纤维胃镜、剖腹术或活组织检查以排除患肝癌的可能性。所有病例都未应用类固醇、抗菌素或其它能够引起胆汁阻塞的药物。
Many clinical studies have shown that copper is related in some ways to the clinical course of the tumor. In patients with lymphoma and some solid tumors, especially breast cancer, gastrointestinal cancer, and lung cancer, the serum copper (Scu) content increased. Scu appears to be associated with the clinical course and extent of tumors and is therefore considered to be one of the better indicators of prognosis for cancer patients. This article aims to investigate the predictive value of Scu in patients with chronic liver dysfunction, the application of differential diagnosis of liver cancer and cirrhosis, and whether it is related to the survival time of liver cancer patients. The author reported a total of 36 patients with primary liver cancer, including 25 males Of 11 women, aged 14 to 75 years, 32 cases were hepatocellular carcinoma, of which 10 cases had cirrhosis and 4 cases had cholangiocarcinoma. Fifteen patients underwent surgical treatment. Forty-seven patients with cirrhosis were in the control group, including 31 males and 16 females. All patients underwent CT, ultrasound X-ray tomography, gastroscopy, laparotomy, or biopsy to rule out the possibility of liver cancer. No steroids, antibiotics, or other drugs that could cause bile obstruction were used in all cases.